12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Heplisav regulatory update

FDA agreed to expand the age range of the proposed indication for Dynavax's Heplisav HBV vaccine. Dynavax now plans to submit a BLA for Heplisav...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >